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Promotor geneAbstract Aim of the work: The present study was undertaken to determine whether mannose
binding lectin-2 (MBL2) promotor-221X/Y gene polymorphism had a possible association with sys-
temic lupus erythematosus (SLE) in Mansoura city.
Patients and methods: We analyzed functional polymorphisms in the promoter of MBL2 gene in
106 Egyptian SLE patients and 99 healthy controls by polymerase chain reaction–restriction frag-
ment length polymorphism (PCR–RFLP). SLE disease activity was evaluated using SLE Disease
Activity Index (SLEDAI) and organ damage was evaluated using SLE International Collaborating
Clinic Damage Index (SLICC/DI).
Results: The patients were 95 females and 11 males with a mean age of 34.4 ± 10.2 years and
disease duration of 4 ± 3.03 years. Genotype frequencies of MBL2 were significantly different
between patients and controls. The YY genotype was significantly associated with SLE in 77
(72.6%) patients compared to the control in 59 (59.6%) (p= 0.048). The XY genotype was in
29 (27.4%) patients and in 40 (40.4%) control. An association was found between the XY genotype
and alopecia (p= 0.048), central nervous system involvement (p= 0.03), vasculitis (p= 0.004) and
anti-phospholipid syndrome (p= 0.001) while the YY genotype was associated with discoid rash,
low serum complement level (C3; p= 0.014 and C4; p= 0.008) and with the presence of anticar-
diolipin antibodies (p= 0.032). MBL genotype did not show any correlation with SLEDAI or
SLICC/DI.
Conclusion: Our results indicate that MBL2 promotor-221X/Y polymorphism is a possible
key-player for SLE development as well as the occurrence of some clinical and laboratory features.l.: +20
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MBL2.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease that displays a complex spectrum of clinical and
immunologic manifestations [1]. It is characterized by a break-
down of self-tolerance and auto-reactive lymphocyte activa-
tion against several nuclear and cytoplasmic self-antigens.
SLE pathogenesis is multifactorial, and its susceptibility has
been associated with genetic, hormonal, immunologic and
environmental factors [2,3]. In a study on Egyptian SLE
patients it has been suggested that anti-complement1q (C1q)
antibodies in combination with anti-double stranded deoxyri-
bonucleic acid (dsDNA) antibodies may serve as potential reli-
able and none invasive markers of SLE disease activity and
renal involvement to avoid unnecessary renal biopsies [4].
The ever-increasing researches concerning various genes
association with SLE emphasized the contribution of the
innate and adaptive immune response genes [5–8]. Mannose
binding lectin (MBL) is a main member of the complement sys-
tem that is responsible for a vital role in innate immunity.
MBL2 gene was detected at the position 10q11.2-21 on chro-
mosome 10. It consists of four exons and three introns. There
were two functional single nucleotide polymorphisms (SNPs)
in the promotor region of the gene, one located at the position
-221 (rs709606 C-G) and the other -550 (rs11003125) and three
functional SNPs in exon 1 at codons 52 (C/T, rs5030737), 54
(G/A, rs1800450), and 57 (G/A, rs1800451), known as D, B,
and C variant, respectively [9,10]. SNPs of MBL2 gene are usu-
ally associated with differential serum MBL level production
and considerable reduction or complete absence of functional
MBL protein [11,12].
Previous studies suggested that deficiency or low MBL
serum levels determined by MBL2 functional SNPs are associ-
ated with autoimmune diseases occurrence [13,14]. The associ-
ation between MBL2 polymorphisms and SLE development as
well as clinical manifestations has been reported. Nevertheless,
controversial results have been obtained among various popu-
lations [2,15]. In addition, it has been shown that anti-MBL
autoantibodies were present in serum of 52% SLE patients
[16].
In various populations, MBL2 represents candidate gene
for SLE susceptibility [17–19]. It has not been studied among
SLE Egyptians while, a recent study detected its association
with Egyptian infants with acute respiratory tract infection
[20]. The aim of this study was to determine the possible asso-
ciation between MBL2 promotor gene polymorphism and
Egyptian SLE patients.2. Patients and methods
A case control study was carried out on 106 SLE Egyptian
patients and 99 healthy volunteers selected as control in the
period from March 2013 to March 2015. Our patients were
selected from the Rheumatology and Rehabilitation, Nephrol-ogy, Internal Medicine and Clinical Pathology Department at
Mansoura University Hospitals. All patients fulfilled the sys-
temic lupus international collaborating clinics classification
criteria for SLE [21]. Drug induced lupus and patients with
other autoimmune disease were excluded. The study was
approved by the Ethics Committee of Mansoura University
Hospital. Written informed consent was obtained from all
patients.
All patients were subjected to full history taking, complete
clinical examination. Disease activity was estimated by SLE
Disease Activity Index (SLEDAI) [22]. Disease severity was
estimated by systemic lupus international collaborating
clinic/American college of rheumatology damage index
(SLICC ACR DI) [23]. Renal biopsy was performed on 74
patients who had persistent proteinuria and/or cellular cast.
Patients were classified according to International Society of
Nephrology/Renal Pathology Society (ISN/RPS) in 2003 clas-
sification of lupus nephritis [24].
2.1. MBL2 gene-221 X/Y promoter region polymorphism
genotyping
3 ml of venous blood was collected by clean venipuncture
using plastic disposable syringes evacuated in screw capped
EDTA tubes and frozen at 20 C until the time of assays.
This work was carried out at the molecular biology laboratory
(Clinical Immunology Unit), Clinical Pathology Department,
Faculty of Medicine, Mansoura University. DNA extraction
was done using QIAamp Mini spin column (Qiagen), cat no.
51104. USA and was used for genotyping assays with the poly-
merase chain reaction–restriction fragment length polymor-
phism (PCR–RFLP) method. The PCR primers were:
(forward) 50-GTTTCCACTCATTCTCATTCCCTAAG-30
and (reverse) 50-GAAAACTCAGGGAAGGTTAATCT
CAG-30 [25].
2.2. Statistical analysis
Categorical data were expressed in numbers and percentages.
Data were expressed as mean ± SD or medians and ranges.
Independent sample T and Mann–Whitney U tests were used
for normally and non-normally distributed data respectively.
The association between categorical variables was determined
by Chi square or Fisher exact test. Spearman’s rho was used to
delineate the correlation between numeric indices. Statistical
significance was considered at p value <0.05. Data entry and
statistical analyses were performed using SPSS (statistical
package of social sciences) version 21 (SPSS Inc., Chicago,
IL, USA).
3. Results
One hundred and six SLE patients: 95 females and 11 males
(female:male 8.6:1) with a mean age of 34.4 ± 10.2 years and
Table 2 MBL2 -221X/Y promotor gene polymorphism in
SLE patients and controls.
MBL2 -221X/Y
n(%)
SLE
patients
(n= 106)
Controls
(n= 99)
Odds ratio
(95% CI)
p
Genotype YY 77 (72.6) 59 (59.6) 1 0.048
XY 29 (27.4) 40 (40.4) 0.3 (0.3–0.99)
Allele Y 183 (86.3) 158 (79.8) 1 0.07
X 29 (13.7) 40 (20.2) 0.62 (0.4–1.1)
MBL: mannose binding lectin, SLE: systemic lupus erythematosus.
Bold value is significant at p< 0.05. Alleles are considered 212 in
SLE patients and 198 in controls.
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SLE was in 7 (6.6%) patients and 18 (16.9%) had positive con-
sanguinity. Healthy control group was 90 female and 9 male
(female:male 10:1) with a mean age of 37.5 ± 7.3 years.
The clinical and laboratory characteristics of the patients
are described in Table 1. Renal biopsy was performed in 74
(69.8%) of SLE patients and lupus nephritis classes were class
II in 3 (2.8%) patients, class III in 45 (42.5%) and class IV in
26 (24.5%) while 32 (30.2%) patients did not undergo renal
biopsy.
3.1. MBL2-221 X/Y promotor polymorphism
There were 77 (72.6%) SLE patients having the genotype YY
while only 29 (27.4%) had the genotype XY. The YY genotype
was significantly associated with SLE compared to the control
(n= 59; 59.6%) (p= 0.048). However, allele frequency
between patients and control groups did not detect any associ-
ation (Table 2).
The relation of MBL2-221X/Y promotor polymorphism
with clinical manifestations is presented in Table 3. Studying
the MBL2 promotor gene polymorphism in SLE patients
demonstrated a significant association of XY genotype withTable 1 Clinical and laboratory characteristics of SLE
patients.
Characteristic No. (%) SLE patients (n= 106)
Positive family history 7 (6.6)
Positive consanguinity 18 (16.9)
Mucocutaneous Malar rash 73 (68.9)
Discoid rash 27 (25.5)
Alopecia 9 (8.5)
Photosensitivity 69 (65.1)
Oral ulcers 61 (57.5)
Hair loss 72 (67.9)
Raynaud’s 12 (11.3)
Articular Arthritis 15 (14.2)
Arthralgia 63 (59.4)
Systemic Cardiac 18 (17)
Pulmonary 17 (16)
CNS involvement 11 (10.4)
Renal involvement 73 (68.8)
GI involvement 22 (20.8)
Vasculitis 11 (10.4)
AIHA 7 (6.6)
APS 11 (10.4)
Laboratory Anemia 79 (74.5)
Leukopenia 11 (10.4)
Thrombocytopenia 12 (11.3)
High ESR 87 (82.1)
High CRP 46 (43.4)
Positive ANA 104 (98.1)
Positive Anti ds DNA 83 (78.3)
Consumed C3 46 (43.4)
C4 44 (41.5)
Positive ACL abs 22 (20.8)
SLE: systemic lupus erythematosus, CNS: central nervous system,
GI: gastrointestinal, AIHA: auto immune hemolytic anemia, APS:
antiphospholipid syndrome, ESR: erythrocyte sedimentation rate,
CRP: C-reactive protein, ANA: anti nuclear antibodies, C: com-
plement, dsDNA: double stranded deoxyribonucleic acid, ACL
abs: anti cardiolipin antibodies.weight loss (p= 0.027), discoid rash (p= 0.027), alopecia
(p= 0.048), neurological symptoms (p= 0.033), vasculitis
(p= 0.004), and APL syndrome (p= 0.001), while other vari-
ables did not demonstrate any significant associations
(p> 0.05). There were no significant correlation between
MBL2 promoter genotype with the SLEDAI (r= 0.17,
p= 0.08) or SLICC/ACRDI (r= 0.05, p= 0.58).
The relation of the MBL2-221X/Y promotor gene poly-
morphism with the laboratory investigations in the SLE
patients is shown in Table 4. The MBL2 promotor YY geno-
type displayed a significant association with low serum com-
plement (p= 0.014) and with the presence of ACL
antibodies (p= 0.032). Other measured laboratory data did
not display any significant association.
4. Discussion
Within the studies of genetic susceptibility to SLE, there is
growing interest in the clinical significance of MBL variant
alleles [26–29]. Preliminary studies in the UK, Spain, China
and Greece suggested a possible association between MBL2
promotor genotype and SLE [30,31].
In the current study, a significant association was found
between SLE and the YY genotype of MBL2-221 X/Y thus
conferring increased disease susceptibility. These results are
similar to earlier Chinese [31] and African [32] studies which
reported an association between SLE and genotype YY.
Contrary to our findings, a meta-analysis involving several
European, Asian and African studies concluded that X allele
was a risk factor for developing SLE [33]. This disagreement
may be explained by different assay techniques used and ethnic
differences or by the influence of another significant promotor
polymorphism at -550 H/L which can influence the secreting
serum MBL level. Furthermore, some researchers have
reported an association between certain MBL promotor geno-
type and increased incidence of clinical manifestations [34–38].
We have investigated the possible association of MBL2-221X/
Y promotor genotype with the broader spectrum of the SLE
patient’s gender, age at disease onset and clinical manifesta-
tions. No association was found with the patients’ gender
which may be due to the limited number of male participants.
Furthermore, no association was found with the age at disease
onset which was in agreement with a Chinese study [39] even
though they included 150 juvenile onset SLE patients. In dis-
agreement to our work, a study from Denmark reported a sig-
nificant association between XY genotype and early onset SLE
Table 3 The association between MBL2 -221X/Y promotor genotype and SLE clinical characteristics.
Characteristic mean ± SD or n (%) MBL2-221X/Y in SLE patients (n= 106)
YY (n= 77) XY (n= 29) P
Age (years) 35 ± 10 33 ± 10 0.38
Age at onset (years) 30 ± 9.2 28 ± 9.8 0.34
Sex Female 70 (73.7) 25 (26.3) 0.49
Male 7 (63.6) 4 (36.4)
General Fever 25 (78.1) 7 (21.9) 0.41
Weight loss 15 (55.6) 12 (44.4) 0.03
Anorexia 62 (72.1) 24 (27.9) 0.79
Mucocutaneous Malar rash 55 (75.3) 18 (24.7) 0.35
Discoid rash 15 (55.6) 12 (44.4) 0.03
Alopecia 4 (44.4) 5 (55.6) 0.048
Photosensitivity 49 (71) 20 (29) 0.61
Oral ulcers 42 (68.9) 19 (31.1) 0.31
Hair loss 51 (70.8) 21 (29.2) 0.54
Raynaud’s 9 (75) 3 (25) 0.86
Articular Arthritis 11 (73.3) 4 (26.7) 0.95
Arthralgia 45 (71.4) 18 (28.6) 0.74
Systemic Cardiac 12 (66.7) 6 (33.3) 0.54
Pulmonary 11 (64.7) 6 (35.3) 0.43
CNS involvement 5 (45.5) 6 (54.5) 0.03
Renal involvement 55 (74.3) 19 (25.7) 0.56
GIT involvement 14 (63.6) 8 (36.4) 0.29
Vasculitis 3 (30) 7 (70) 0.004
AIHA 5 (71.4) 2 (28.6) 0.94
APS 3 (27.3) 8 (72.7) 0.001
SLE: systemic lupus erythematosus, CNS: central nervous system, GIT: gastrointestinal tract, AIHA: auto immune hemolytic anemia, APS:
antiphospholipid syndrome. Bold values are significant at p< 0.05.
Table 4 The association between MBL2 genotype and labo-
ratory investigations for SLE patients.
Laboratory investigations
n (%)
MBL2-221X/Y in SLE patients
(n= 106)
YY
(n= 77)
XY
(n= 29)
P
Anemia 61 (77.2) 18 (22.8) 0.07
Leukopenia 9 (81.8) 2 (18.2) 0.45
Thrombocytopenia 9 (75) 3 (25) 0.84
High ESR 65 (74.7) 22 (25.3) 0.31
High CRP 30 (65.2) 16 (34.8) 0.13
Positive ANA 75 (72.1) 29 (27.9) 0.38
Positive anti ds DNA 61 (73.5) 22 (26.5) 0.71
Positive ACL ab 12 (54.5) 10 (45.5) 0.032
Consumed C3
C4
39 (84.8)
38 (86.4)
7 (15.2)
6 (13.6)
0.014
0.008
SLE: systemic lupus erythematosus, ESR: erythrocyte sedimenta-
tion rate, CRP: C reactive protein, ANA: anti nuclear antibodies,
C: complement, dsDNA: double stranded deoxyribonucleic acid,
ACL abs: anti cardiolipin antibodies. Bold values are significant at
p< 0.05.
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typing techniques as they used PCR-sequence specific priming
rather than the PCR–RFLP used in this study.
In our study we detected a significant association between
XY genotype and weight loss, discoid rash and alopecia. In
accordance to these findings, another study [40] comparingMBL promotor genotype effect between SLE and dermato-
myositis patients detected a significant association between
XY genotype and cutaneous symptoms only in SLE patients.
On the other hand, our results disagree with that of an earlier
Danish study on 315 patients [34] and this difference could be
due to the variation between populations in SLE symptoms or
in the number of participants. In the present study there was a
significant association between XY genotype and APL syn-
drome which confirmed the findings on a Caucasian [41] and
Brazilian [42] population. The significant association between
vasculitis and XY genotype in the current study verified the
findings of a previous study [41]. A significant association
between XY genotype and the neurological symptoms was
detected. However, in Southern Brazil they could not detect
any association [40]. This difference could be explained by
the difference in ethnic populations. Although we had a high
frequency of lupus nephritis (LN) we did not detect any asso-
ciation with MBL genotype. Our result was in agreement with
studies on different ethnic groups [15,34,39,40]. However, in
another study from Tanta on Egyptian SLE patients, MBL2
mutant genotypes AO+ OO were significantly higher in
SLE patients compared to control and were more likely to pro-
duce anti-ds DNA and be associated with LN [42]. Significant
association with renal failure has been reported [41]. However,
we could not support this finding because none of our patients
had renal failure.
In this study, we did not detect any association between car-
diac manifestations and MBL genotype. Our result confirms a
previous study on Chinese children [39] and is in disconformity
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number of participants. They detected a significant 3.3 times
higher association between cardiac affection and XY genotype.
This could be explained by the different genotyping method
used. In another Egyptian study on SLE patients, MBL A/B
and B/B were significantly higher (47%) than in the control
(29%) and were significantly associated with increased
intima-media thickness, dyslipidemia, increased disease activ-
ity and hypocomplementemia suggesting its role as a risk fac-
tor for atherosclerosis [43]. No association was found between
MBL2 genotype and pulmonary or GIT symptoms which is in
accordance to the findings of another study on Chinese chil-
dren [39]. There was no association between MBL2 genotype
and autoimmune hemolytic anemia which is consistent with
that of other studies carried out on different ethnicities
[39,40,44].
In the current study the YY genotype was significantly
associated only with the low serum complement level. On the
contrary, another study [41] recorded an association between
hypocomplementemia and the XY genotype. However this
could be explained by different degrees of activity between
both studies. In our study, XY genotype had only a significant
association with positive serum ACL antibodies. Our finding is
in harmony with those of reports from Caucasian [41] and
Brazilian [44] populations.
In this study, SLEDAI did not correlate with MBL2 pro-
motor genotype. This agrees with the results of other studies
[15,34,39]. But in a long term follow up study, there was a sig-
nificant correlation between SLEDAI and XY genotype [45].
Additionally, in this study, SLICC/ACR DI did not correlate
with MBL2 promotor genotype. A significant correlation
between SLICC/ACR DI and XY genotype was only detected
once [41] in a study including 11 patients with renal failure
which was absent in the present study.
In conclusion, our study pinpoints MBL2 -221X/Y gene
promotor polymorphisms as possible key-players in SLE
development. Moreover, it also seems to be associated with
some clinical and laboratory manifestations of SLE. Further
studies are needed to clarify the role of MBL2 promotor gene
polymorphism and other SNPs in SLE with long term follow
up. A regression test would be of value to detect the role of
MBL as a risk factor for SLE activity and manifestations.
Another study is needed to compare serum MBL level among
significant SNPs and follow up its level during SLE remission
and exacerbation.
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